현대바이오랜드
Financials
Valuation Metrics
현대바이오랜드's Market Cap is ₩1082B. At end of 2025 it was ₩1289B. Ranked #1190 of 2,436 in KR market (top 49%), #626 of 1,649 on KOSDAQ (top 38%), #27 of 57 in Household & Personal Products (top 47%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 108.15B KRW | KR#1,190/2,436 Sec#27/57 |
| Revenue | 135.04B KRW | KR#1,228/2,436 Sec#27/57 |
| Net Income | 12.48B KRW | KR#825/2,436 Sec#21/57 |
| Total Assets | 161.49B KRW | KR#1,418/2,436 Sec#28/57 |
| Net Assets | 139.64B KRW | KR#1,156/2,436 Sec#22/57 |
| Employees | 347 | KR#691/2,436 Sec#15/57 |
| Value | ||
| P/E | 8.67x | KR#607/2,436 Sec#9/57 |
| P/B | 0.77x | KR#1,253/2,436 Sec#26/57 |
| P/S | 0.80x | KR#1,240/2,436 Sec#28/57 |
| EV/EBITDA | 8.18x | KR#475/2,436 Sec#9/57 |
| FCF Yield | 14.31% | KR#470/2,436 Sec#5/57 |
| Profitability | ||
| ROE | 8.94% | KR#596/2,436 Sec#16/57 |
| ROA | 7.73% | KR#363/2,436 Sec#12/57 |
| Op. Margin | 9.58% | KR#514/2,436 Sec#12/57 |
| Revenue Growth | 13.45% | KR#800/2,436 Sec#22/57 |
| Financial Health | ||
| Debt Ratio | 115.64% | KR#552/2,436 Sec#18/57 |
| Total Debt | 6.00B KRW | KR#1,747/2,436 Sec#40/57 |
| FCF | 15.48B KRW | KR#586/2,436 Sec#14/57 |
| Cash | 8.27B KRW | KR#1,777/2,436 Sec#35/57 |
| Current Ratio | 4.49x | KR#341/2,436 Sec#8/57 |
| Net Debt/EBITDA | -0.18x | KR#653/2,436 Sec#22/57 |
| Dividend | ||
| Div. Yield | 2.00% | KR#896/2,436 Sec#20/57 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/57 |
| Performance | ||
| 1Y Return | -26.88% | KR#1,477/2,436 Sec#24/57 |
| 1M Return | 1.84% | KR#733/2,436 Sec#29/57 |
| From 52W High | -32.24% | KR#481/2,436 Sec#16/57 |
| 1Y MDD | -38.67% | KR#475/2,436 Sec#6/57 |
| Trading | ||
| Volume | 64,487 shares | KR#779/2,436 Sec#13/57 |
| Foreign Own. | 2.40% | KR—/2,436 Sec—/57 |
| Per Share | ||
| EPS | 416 KRW | KR#980/2,436 Sec#24/57 |
| BPS | 4,655 KRW | KR#1,496/2,436 Sec#33/57 |
Company Info
Hyundaibioland was established in 1995 to manufacture and sell natural product cosmetic and functional food ingredients, listing on KOSDAQ in 2001. The company operates in cosmetic ingredients, health functional foods, pharmaceutical ingredients, medical devices, and brand distribution, leveraging natural-derived biomaterials. It focuses on discovering natural materials and R&D to enhance global competitiveness and develop next-generation Big Items through convergence technology, in response to stricter environmental regulations. Hyundaibioland is headquartered in Cheongju-si, Chungcheongbuk-do.